Does the media favor AUTL or BHVN?

In the previous week, Biohaven had 8 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for Biohaven and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Biohaven's score of -0.15 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ABCL or AUTL?

In the previous week, AbCellera Biologics and AbCellera Biologics both had 5 articles in the media. AbCellera Biologics' average media sentiment score of 1.03 beat Autolus Therapeutics' score of 0.49 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUTL or STOK?

In the previous week, Stoke Therapeutics had 9 more articles in the media than Autolus Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Stoke Therapeutics' score of 0.28 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUTL or AUPH?

In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Autolus Therapeutics. MarketBeat recorded 12 mentions for Aurinia Pharmaceuticals and 5 mentions for Autolus Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 0.60 beat Autolus Therapeutics' score of 0.49 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MESO or AUTL?

Autolus Therapeutics has a consensus price target of $10.00, indicating a potential upside of 314.94%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88

Does the media refer more to MESO or AUTL?

In the previous week, Mesoblast had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Mesoblast and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Mesoblast's score of 0.01 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Autolus Therapeutics (AUTL) Competitors

$2.41 -0.05 (-2.03%)

As of 08/21/2026 04:00 PM Eastern

Compare

AUTL vs. BHVN, ABCL, STOK, AUPH, and MESO

Should you buy Autolus Therapeutics stock or one of its competitors? Autolus Therapeutics's main competitors and comparable companies include Biohaven (BHVN), AbCellera Biologics (ABCL), Stoke Therapeutics (STOK), Aurinia Pharmaceuticals (AUPH), and Mesoblast (MESO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Autolus Therapeutics compare to Biohaven?

Autolus Therapeutics (NASDAQ:AUTL) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Autolus Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, Biohaven had 8 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for Biohaven and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Biohaven's score of -0.15 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biohaven has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Autolus Therapeutics' return on equity of -178.66% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Biohaven	N/A	-1,328.94%	-138.27%

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Autolus Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	8.51	-$287.53M	-$1.06	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Autolus Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 314.94%. Biohaven has a consensus price target of $21.75, indicating a potential upside of 56.36%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65

Summary

Autolus Therapeutics beats Biohaven on 11 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Autolus Therapeutics (NASDAQ:AUTL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Autolus Therapeutics has a net margin of -238.66% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

AbCellera Biologics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

In the previous week, AbCellera Biologics and AbCellera Biologics both had 5 articles in the media. AbCellera Biologics' average media sentiment score of 1.03 beat Autolus Therapeutics' score of 0.49 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics has higher earnings, but lower revenue than Autolus Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A
Autolus Therapeutics	$75.39M	8.51	-$287.53M	-$1.06	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AbCellera Biologics presently has a consensus price target of $12.83, indicating a potential upside of 13.37%. Autolus Therapeutics has a consensus price target of $10.00, indicating a potential upside of 314.94%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Autolus Therapeutics beats AbCellera Biologics on 8 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Stoke Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Stoke Therapeutics has higher revenue and earnings than Autolus Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	8.51	-$287.53M	-$1.06	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

Autolus Therapeutics has a net margin of -238.66% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Autolus Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Autolus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 314.94%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 37.04%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Autolus Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Stoke Therapeutics had 9 more articles in the media than Autolus Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Stoke Therapeutics' score of 0.28 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Aurinia Pharmaceuticals?

Autolus Therapeutics (NASDAQ:AUTL) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Autolus Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Autolus Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 314.94%. Aurinia Pharmaceuticals has a consensus target price of $17.67, indicating a potential upside of 6.11%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Autolus Therapeutics' net margin of -238.66%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Aurinia Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	8.51	-$287.53M	-$1.06	N/A
Aurinia Pharmaceuticals	$311.51M	7.11	$287.20M	$2.29	7.27

In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Autolus Therapeutics. MarketBeat recorded 12 mentions for Aurinia Pharmaceuticals and 5 mentions for Autolus Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 0.60 beat Autolus Therapeutics' score of 0.49 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aurinia Pharmaceuticals beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Autolus Therapeutics (NASDAQ:AUTL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mesoblast had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Mesoblast and 5 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.49 beat Mesoblast's score of 0.01 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Autolus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher earnings, but lower revenue than Autolus Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A
Autolus Therapeutics	$75.39M	8.51	-$287.53M	-$1.06	N/A

Autolus Therapeutics has a consensus price target of $10.00, indicating a potential upside of 314.94%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Mesoblast has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Mesoblast's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

Summary

Autolus Therapeutics beats Mesoblast on 9 of the 17 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$641.45M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	-2.27	11.62	272.88	24.24
Price / Sales	8.51	1,338.17	618.96	99.76
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	8.61	16.80	13.05	6.20
Net Income	-$287.53M	-$12.50M	$3.47B	$348.59M
7 Day Performance	12.09%	3.29%	2.09%	0.08%
1 Month Performance	58.55%	8.23%	6.64%	3.88%
1 Year Performance	37.71%	55.05%	25.02%	16.98%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	2.7021 of 5 stars	$2.41 -2.0%	$10.00 +314.9%	+37.7%	$641.45M	$75.39M	N/A	330
BHVN Biohaven	3.2482 of 5 stars	$14.58 -0.5%	$21.63 +48.3%	-10.9%	$2.21B	N/A	N/A	239	News Coverage Analyst Revision
ABCL AbCellera Biologics	2.3063 of 5 stars	$9.34 +34.8%	$9.40 +0.6%	+157.9%	$2.12B	$75.13M	N/A	500	Gap Down High Trading Volume
STOK Stoke Therapeutics	2.449 of 5 stars	$32.23 -1.5%	$43.00 +33.4%	+65.1%	$2.11B	$184.42M	N/A	100	Analyst Forecast Insider Trade
AUPH Aurinia Pharmaceuticals	3.509 of 5 stars	$15.45 -2.5%	$17.67 +14.3%	+35.7%	$2.11B	$283.05M	6.75	300	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. BHVN, ABCL, STOK, AUPH, and MESO

How does Autolus Therapeutics compare to Biohaven?

Summary

How does Autolus Therapeutics compare to AbCellera Biologics?

Summary

How does Autolus Therapeutics compare to Stoke Therapeutics?

Summary

How does Autolus Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Autolus Therapeutics compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. BHVN, ABCL, STOK, AUPH, and MESO

How does Autolus Therapeutics compare to Biohaven?

Which has more volatility and risk, AUTL or BHVN?

Does the media favor AUTL or BHVN?

Is AUTL or BHVN more profitable?

Do institutionals & insiders believe in AUTL or BHVN?

Which has better valuation and earnings, AUTL or BHVN?

Do analysts recommend AUTL or BHVN?

Summary

How does Autolus Therapeutics compare to AbCellera Biologics?

Is ABCL or AUTL more profitable?

Which has more volatility and risk, ABCL or AUTL?

Does the media refer more to ABCL or AUTL?

Which has better valuation and earnings, ABCL or AUTL?

Do insiders & institutionals believe in ABCL or AUTL?

Do analysts prefer ABCL or AUTL?

Summary

How does Autolus Therapeutics compare to Stoke Therapeutics?

Which has better earnings and valuation, AUTL or STOK?

Is AUTL or STOK more profitable?

Which has more risk and volatility, AUTL or STOK?

Do analysts prefer AUTL or STOK?

Do institutionals & insiders have more ownership in AUTL or STOK?

Does the media favor AUTL or STOK?

Summary

How does Autolus Therapeutics compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, AUTL or AUPH?

Do analysts prefer AUTL or AUPH?

Is AUTL or AUPH more profitable?

Which has preferable valuation and earnings, AUTL or AUPH?

Does the media favor AUTL or AUPH?

Do institutionals and insiders have more ownership in AUTL or AUPH?

Summary

How does Autolus Therapeutics compare to Mesoblast?

Do insiders and institutionals have more ownership in MESO or AUTL?

Does the media refer more to MESO or AUTL?

Which has preferable earnings and valuation, MESO or AUTL?

Do analysts prefer MESO or AUTL?

Is MESO or AUTL more profitable?

Which has more risk and volatility, MESO or AUTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools